Practical model-based dose finding in early-phase clinical trials: Optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children

Stroke

Volumn 39, Issue 9, 2008, Pages 2627-2636

  Whelan, Harry T ^a   Cook, John D ^b   Amlie Lefond, Catherine M ^a   Hovinga, Collin A ^c   Chan, Anthony K ^d   Ichord, Rebecca N ^e   Deveber, Gabrielle A ^f   Thall, Peter F ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Bayesian statistics; Dose finding; Phase I II trial; Stroke; TPA

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BAYES THEOREM; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER SIMULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAXIMUM TOLERATED DOSE; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; PROBABILITY; REVIEW; SAMPLE SIZE; ADOLESCENT; AGE; ARTICLE; BRAIN ISCHEMIA; CLINICAL PROTOCOL; DRUG TOXICITY; INFANT; METHODOLOGY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; STANDARD; STATISTICAL MODEL; STROKE; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; BAYES THEOREM; BRAIN ISCHEMIA; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FIBRINOLYTIC AGENTS; HUMANS; INFANT; MODELS, STATISTICAL; RESEARCH DESIGN; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 52449120660     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.510164     Document Type: Review

References (31)

1. Giroud M, Lemesle M, Gouyon JB, Nivelon JL, Milan C, Dumas R. Cerebrovascular disease in children under 16 years of age in the city of Dijon, France: a study of incidence and clinical features from 1985 to 1993. J Clin Epidemiol. 1995;48:1343-1348.
2. Govaert P, Matthys E, Zecic A, Roelens F, Oostra A, Vanzieleghem B. Perinatal cortical infarction within middle cerebral artery trunks. Arch Dis Child Fetal Neonatal Ed. 2000;82:F59-F63.
3. deVeber GA, MacGregor D, Curtis R, Mayank S. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol. 2000;15:316-324.
4. Janjua N, Nasar A, Mohammad Y, Qureshi AI. The financial burden of pediatric stroke cannot be undermined in the United States. Stroke. 2006;37:498.
5. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
6. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28: 2109-2118.
7. Khatri P, Khoury JC, Alwell K, Woo D, Kissela BM, Moomaw CJ, Miller R, Cho YJ, Kleindorfer D. Potential rtPA eligibility in children: a population-based study Stroke. 2006;37:641.
8. Rafay M, Pontigon A, Chiang J, Jarvis A, Silver F, MacGregor D, deVeber GA. Eligibility for hyperacute thrombolytic therapy with tissue plasminogen activator (tPA) in children. Ann Neurol. 2006;60:142-143.
9. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood. 1992;80: 1998-2005.
10. Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, De Rosa L, Hamilton S, Ragg P, Robinson S, Auldist A, Crock C, Roy N, Rowlands S. Developmental haemostasis: impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95:362-372.
11. Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb Haemost. 1988;60:361-364.
12. Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fund Clin Pharmacol. 2003;17:281-299.
13. Amlie-Lefond C, Benedict SL, Bernard T, Carpenter J, Chan A, deVeber GA, Dowling MM, Hovinga C, Ichord R, Kirkham F, Kirton A, Tsuchida T, Whelan HT, Zamel K, International Pediatric Stroke Study Investigators. Thrombolysis in children with arterial ischemic stroke: initial results from the International Pediatric Stroke Study. Stroke. 2007; 38:485.
14. Janjua N, Nasar A, Lynch JK, Qureshi AI. Thrombolysis for ischemic stroke in children: data from the nationwide inpatient sample. Stroke. 2007;38:1850-1854.
15. Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics. 2004;60:684-693.
16. Berry DA. Clinical trials: is the Bayesian approach ready for prime time? Yes! Stroke. 2005;36:1621-1622.
17. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med. 1995;14:1149-1161.
18. Thall PF, Lee SJ. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity. Int J Gynecol Cancer. 2003;13: 251-261.
19. Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 1993;5:1-16.
20. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004;35(suppl I):I-2726 -I-2730.
21. Thall PF, Cook JD, Estey EH. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations. J Biopharm Stat. 2006;16:623-638.
22. Thall PF. Some geometric methods for constructing decision criteria based on two-dimensional parameters. J Stat Planning Inference. 2008; 138:516-527.
23. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38:967-973.
24. Tandberg Askevold E, Naess H, Thomassen L. Predictors for recanali-zation after intravenous thrombolysis in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2007;16:21-24.
25. Gupta AA, Leaker M, Andrew M, Massicotte P, Liu L, Benson LN, McCrindle BW. Safety and outcomes of thrombolysis with tissue plas-minogen activator for treatment of intravascular thrombosis in children. J Pediatr. 2001;139:682-688.
26. Gooley TA, Martin PJ, Fisher LD, Pettinger M. Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. Control ClinTrials. 1994;15:450-462.
27. O'Quigley J, Hughes MD, Fenton T. Dose-finding designs for HIV studies. Biometrics. 2001;57:1018 -1029.
28. Braun TM. The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes. Control Clin Trials. 2002;23:240-256.
29. Ivanova A. A new dose-finding design for bivariate outcomes. Biometrics. 2003;59:1001-1007.
30. Bekele BN, Shen Y. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics. 2005;61:343-354.
31. Berry DA, Mueller P, Grieve AP, Smith M, Parke T, Blazek R, Mitchard N, Krams M. Adaptive Bayesian designs for dose-ranging drug trials. Lecture Notes Stat. 2001;2001:99-181.